Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash & Current Investments (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Cash & Current Investments for 12 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 10.81% year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Sep 2025, down 10.81%, and an annual FY2024 reading of $4.2 million, down 63.56% over the prior year.
  • Cash & Current Investments was $5.9 million for Q3 2025 at Arcadia Biosciences, up from $4.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $51.9 million in Q1 2021 and bottomed at $3.2 million in Q1 2025.
  • Average Cash & Current Investments over 5 years is $18.9 million, with a median of $18.5 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments skyrocketed 7229.5% in 2021, then tumbled 63.56% in 2024.
  • Year by year, Cash & Current Investments stood at $28.7 million in 2021, then fell by 28.03% to $20.6 million in 2022, then tumbled by 43.61% to $11.6 million in 2023, then crashed by 63.56% to $4.2 million in 2024, then surged by 38.26% to $5.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for RKDA at $5.9 million in Q3 2025, $4.4 million in Q2 2025, and $3.2 million in Q1 2025.